Indications:
Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older.
Dosage and Administration:
Adults dosage:
One application per 24 hours, at any time suitable for the patient, for as long as facial erythema is present.
The maximum daily recommended dose is 1 g of gel in total weight, which corresponds to approximately five pea sized amounts. Treatment should be initiated with a smaller amount of gel (less than the maximum) for at least one week. The amount of gel can then be increased gradually based on tolerability and patient response.
Pediatric Dosage:
The safety and efficacy of brimonidine in children and adolescents aged less than 18 years have not been established. No data are available. Brimonidine is contraindicated in children aged less than 2 years because of serious systemic safety risk. Safety concerns related to the systemic absorption of brimonidine have also been identified for the age group 2 to 12 years. Brimonidine should not be used in children or adolescents aged 2 to 18 years.
Contraindication:
Hypersensitivity to the active substance or to any of the excipients.
Children aged less than 2 years.
Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.
